drugset / Trial / NCT03130127

Continuous Versus Bolus Infusion of Terlipressin for Portal Hypertension Related Bleeding in Liver Cirrhosis

NCT03130127

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Terlipressin is the mainstay drug for the treatment of acute variceal bleeding in liver cirrhosis. According to the drug instructions, intravenous bolus infusion is the standard approach of terlipressin. It remains unclear about whether or not continuous infusion of terlipressin should be considered.

Timeline

Start
2024-07-01
Primary completion
2025-12-01
Completion
2025-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Terlipressin Peptide Intravenous